QIAGEN N.V. |
Market Closed -
Other stock markets
|
Pre-market 09:26:05 am | |||
| 41.08 USD | -1.06% |
|
41.17 | +0.22% |
Financials (USD)
| Sales 2024 * | 2.01B | Sales 2025 * | 2.14B | Capitalization | 9.09B |
|---|---|---|---|---|---|
| Net income 2024 * | 398M | Net income 2025 * | 442M | EV / Sales 2024 * | 4.67 x |
| Net Debt 2024 * | 300M | Net cash position 2025 * | 281M | EV / Sales 2025 * | 4.11 x |
| P/E ratio 2024 * |
23.2
x | P/E ratio 2025 * |
20.7
x | Employees | 5,361 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on Qiagen N.V.
More recommendations
More press releases
| 1 day | -1.06% | ||
| 1 week | +4.08% | ||
| Current month | -4.44% | ||
| 1 month | -4.06% | ||
| 3 months | -9.60% | ||
| 6 months | +8.08% | ||
| Current year | -8.25% |
1 week
40.56
41.94
1 month
39.0343.42
Current year
39.0347.29
1 year
35.8149.18
3 years
35.8159.79
5 years
25.8160.82
10 years
21.3560.82
| Managers | Title | Age | Since |
|---|---|---|---|
Thierry Bernard
CEO | Chief Executive Officer | 60 | 15-01-31 |
Metin Colpan
FOU | Founder | 69 | 96-04-28 |
Roland Sackers
DFI | Director of Finance/CFO | 56 | 98-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 11-05-31 | |
Metin Colpan
FOU | Founder | 69 | 96-04-28 |
Lawrence Rosen
CHM | Chairman | 66 | 13-06-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.10% | 1 M€ | 0.00% | - | |
| 1.79% | 2 M€ | -.--% | ||
| 1.65% | 2 M€ | +6.77% | ||
| 1.32% | 152 M€ | -1.84% | - | |
| 1.08% | 8 M€ | +2.44% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 41.08 | -1.06% | 1,254,865 |
| 24-04-24 | 41.52 | -0.88% | 816,213 |
| 24-04-23 | 41.89 | +1.63% | 971,222 |
| 24-04-22 | 41.22 | +3.05% | 1,253,769 |
| 24-04-19 | 40 | +1.34% | 1,107,980 |
Delayed Quote Nyse, April 25, 2024 at 04:00 pm EDT
More quotes
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Calendar
2024-04-29
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
41.08
USD
Average target price
50.75
USD
Spread / Average Target
+23.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.25% | 9.09B | |
| +1.12% | 42.59B | |
| +6.77% | 40.65B | |
| +46.73% | 40.57B | |
| -11.96% | 26.77B | |
| +6.01% | 24.81B | |
| -24.92% | 18.17B | |
| -3.63% | 11.7B | |
| +27.16% | 12.05B | |
| +7.30% | 11.1B |
- Stock Market
- Equities
- QGEN Stock
